WO2002060341A3 - Inhibition of proteasomes to prevent restenosis - Google Patents

Inhibition of proteasomes to prevent restenosis Download PDF

Info

Publication number
WO2002060341A3
WO2002060341A3 PCT/US2002/002367 US0202367W WO02060341A3 WO 2002060341 A3 WO2002060341 A3 WO 2002060341A3 US 0202367 W US0202367 W US 0202367W WO 02060341 A3 WO02060341 A3 WO 02060341A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
inhibiting
compound
blood vessel
proteasomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/002367
Other languages
French (fr)
Other versions
WO2002060341A2 (en
Inventor
Stephen E Epstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedStar Health
Original Assignee
MedStar Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedStar Health filed Critical MedStar Health
Priority to EP02713482A priority Critical patent/EP1365754A2/en
Priority to AU2002245330A priority patent/AU2002245330A1/en
Priority to US10/470,533 priority patent/US20040116329A1/en
Publication of WO2002060341A2 publication Critical patent/WO2002060341A2/en
Publication of WO2002060341A3 publication Critical patent/WO2002060341A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Restenosis of blood vessels after angioplasty is achieved by preventing of cell proliferation, particularly of smooth muscle cells, in blood vessel walls by inhibiting the ubiquitin-proteasome protein degradation pathway. The inhibition is accomplished by administering to the cells in the blood vessel walls a compound, e.g., a protein or small molecule, capable of inhibiting the ubiquitin-proteasome protein degradation pathway. The inhibiting compound is preferably administered by coating the compound on a stent and implanting the stent in the blood vessel after angioplasty.
PCT/US2002/002367 2001-01-30 2002-01-29 Inhibition of proteasomes to prevent restenosis Ceased WO2002060341A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02713482A EP1365754A2 (en) 2001-01-30 2002-01-29 Inhibition of proteasomes to prevent restenosis
AU2002245330A AU2002245330A1 (en) 2001-01-30 2002-01-29 Inhibition of proteasomes to prevent restenosis
US10/470,533 US20040116329A1 (en) 2002-01-29 2002-01-29 Inhibition of proteasomes to prevent restenosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26473501P 2001-01-30 2001-01-30
US60/264,735 2001-01-30

Publications (2)

Publication Number Publication Date
WO2002060341A2 WO2002060341A2 (en) 2002-08-08
WO2002060341A3 true WO2002060341A3 (en) 2002-10-17

Family

ID=23007382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002367 Ceased WO2002060341A2 (en) 2001-01-30 2002-01-29 Inhibition of proteasomes to prevent restenosis

Country Status (3)

Country Link
EP (1) EP1365754A2 (en)
AU (1) AU2002245330A1 (en)
WO (1) WO2002060341A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61840B1 (en) 2004-07-02 2021-06-30 Geron Corp Synthesis of protected 3'-amino 5'-phosphoramidite nucleoside monomers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Enrollment completed for phase II trial of LDP-341", DRUG WEEK, 2 November 2001 (2001-11-02), pages 36 - 37, XP002953667 *
"Old and new drug may fight myeloma", SCIENCE NEWS, vol. 158, 16 December 2000 (2000-12-16), pages 399, XP002953669 *
CHRISTENSEN, D.: "Things just mesh", SCIENCE NEWS, vol. 160, 24 November 2001 (2001-11-24), pages 328 - 330, XP002953670 *
HENDERSON, C. W.: "Sirolimus-coated stent still effective at 12 months' follow-up", BIOTECH. WEEK, 17 January 2001 (2001-01-17), pages 1 - 2, XP002953671 *
KOHN, C.: "Proteasome inhibitor shows promise for patients with refractory disease", DRUG WEEK, 25 January 2002 (2002-01-25), pages 21 - 22, XP002953668 *
RUTH, J.-P. S.: "Stock to watch: Johnson & Johnson", BUSINESS NEWS, vol. 14, 11 September 2001 (2001-09-11), pages 1 - 2, XP002953672 *

Also Published As

Publication number Publication date
WO2002060341A2 (en) 2002-08-08
EP1365754A2 (en) 2003-12-03
AU2002245330A1 (en) 2002-08-12

Similar Documents

Publication Publication Date Title
WO2004037310A3 (en) Surface coating comprising bioactive compound
WO1998043618A3 (en) Use of cytoskeletal inhibitors for the prevention of restenosis
WO2004000379A8 (en) Stent coatings with sustained drug release rate
WO2001047572A3 (en) Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
IL131450A0 (en) 1,5-Dihydro-pyrazolo [3,4-d]-pyrimidinone derivatives
AU2003298880A1 (en) Coating for implantable devices and a method of forming the same
DE60026513D1 (en) LOCAL DRUG DELIVERY
AU4787496A (en) Coating for bio-material insertable into the bloodstream or tissue of the human body
WO2002058753A3 (en) Coating for implantable devices and a method of forming the same
WO2005096990A3 (en) Novel modification of medical prostheses
WO2002072084A3 (en) Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
HUP0401196A3 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity, process for their preparation and pharmaceutical compositions containing them for the treatment of hyperlipidaemia
EP1674079A3 (en) Pressurised metered dose inhalers (MDI)
IT1312377B1 (en) COMPOSITIONS BASED ON TIOTIC ACID, CISTEIN AND / OR N-ACETYL CISTEINADA USE IN PHARMACEUTICAL, DIETETIC AND COSMETIC PREPARATIONS
WO2004098495A3 (en) Medical devices and methods for inhibiting proliferation of smooth muscle cells
WO2000033790A3 (en) Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs
WO2002100148A3 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
DK1272169T3 (en) Use of 13-head as regulator of vascular biocompatibility and as inhibitor of cellular hyperplasia
WO2003032809A3 (en) Modulation of akt-dependent response to prevent restenosis
DK1567171T3 (en) Use of dextran sulfate for the treatment of ibmir
WO2003061597A3 (en) Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
PL1667746T3 (en) Bioartificial implant and its use and method of reducing the risk for formation of connective tissue after implantation
WO2002087472A8 (en) Stent-based delivery of statins to prevent restenosis
WO2003099228A8 (en) Compositions and processes for inhibiting gene expression using polynucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002713482

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002713482

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10470533

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP